Nomura Holdings’s MoonLake Immunotherapeutics MLTX Stock Holding History

Nomura Holdings’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$71.7K	–	2057
2025 Q3	$71.7K	Buy	+10,000	New	+$521K	﹤0.01%	1820

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Nomura Holdings's MLTX Position: Q2 2022 in Review

Nomura Holdings sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 22,733 shares — an estimated $239K sold.

Nomura Holdings first reported a position in MLTX in Q1 2021 and held it in 5 quarters. The position peaked at $259K in Q1 2021. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

Nomura Holdings reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
Nomura Holdings sold 22,733 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $239K.
Nomura Holdings first reported a position in MoonLake Immunotherapeutics in Q1 2021 and held it in 5 quarters.
Nomura Holdings's MoonLake Immunotherapeutics position peaked at $259K in Q1 2021.
23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Nomura Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.